Weight | 1 lbs |
---|---|
Dimensions | 9 × 5 × 2 in |
host | chicken |
isotype | IgY |
clonality | polyclonal |
concentration | 1 mg/mL |
applications | ICC/IF, IHC, WB |
reactivity | human, mouse, rat |
available sizes | 1 mg, 100 µg, 25 µg |
chicken anti-GFAP polyclonal antibody 6048
$100.00 – $2,600.00
Antibody summary
- Chicken polyclonal to GFAP
- Suitable for: WB, ICC/IF, IHC
- Reacts with: human, mouse, rat
- Isotype: IgY
- 100 µg, 25 µg, 1 mg
chicken anti-GFAP polyclonal antibody 6048
target relevance |
---|
Glial Fibrillary Acidic Protein (GFAP) is a crucial cell marker widely employed in neuroscience and neurobiology research. It is an intermediate filament protein primarily found in astrocytes, a type of glial cell in the central nervous system. GFAP serves as a reliable marker for identifying and characterizing astrocytes in various experimental models and tissues. Immunohistochemistry and immunofluorescence techniques using antibodies targeting GFAP enable researchers to visualize and quantify astrocytic populations, gaining insights into their distribution, morphology, and function in the brain. Moreover, GFAP antibodies are instrumental in studying astrocyte reactivity, a phenomenon occurring in response to brain injury or neurodegenerative diseases. As astrocytes play critical roles in neural development, neurotransmitter regulation, and maintenance of the blood-brain barrier, GFAP has proven indispensable in advancing our understanding of glial biology and its contribution to neurological disorders. Click for more on: cell markers and GFAP |
Protein names Glial fibrillary acidic protein (GFAP) |
Gene names GFAP,GFAP |
Protein family Intermediate filament family |
Mass 49880Da |
Function FUNCTION: GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells. |
Subellular location SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12058025}. Note=Associated with intermediate filaments. {ECO:0000269|PubMed:12058025}. |
Tissues TISSUE SPECIFICITY: Expressed in cells lacking fibronectin. {ECO:0000269|PubMed:1847665}. |
Structure SUBUNIT: Interacts with SYNM. {ECO:0000250|UniProtKB:P03995}.; SUBUNIT: [Isoform 2]: Interacts with PSEN1 (via N-terminus). {ECO:0000269|PubMed:12058025}. |
Post-translational modification PTM: Phosphorylated by PKN1. {ECO:0000269|PubMed:12686604, ECO:0000269|PubMed:9099667, ECO:0000269|PubMed:9175763}. |
Involvement in disease DISEASE: Alexander disease (ALXDRD) [MIM:203450]: A rare disorder of the central nervous system. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death within the first decade. Infants with Alexander disease develop a leukodystrophy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course. Histologically, Alexander disease is characterized by Rosenthal fibers, homogeneous eosinophilic inclusions in astrocytes. {ECO:0000269|PubMed:11138011, ECO:0000269|PubMed:11567214, ECO:0000269|PubMed:11595337, ECO:0000269|PubMed:12034785, ECO:0000269|PubMed:12034796, ECO:0000269|PubMed:12581808, ECO:0000269|PubMed:12944715, ECO:0000269|PubMed:12975300, ECO:0000269|PubMed:15030911, ECO:0000269|PubMed:15732097, ECO:0000269|PubMed:17043438, ECO:0000269|PubMed:17805552, ECO:0000269|PubMed:17894839, ECO:0000269|PubMed:17934883, ECO:0000269|PubMed:17960815, ECO:0000269|PubMed:18004641, ECO:0000269|PubMed:18079314, ECO:0000269|PubMed:19412928, ECO:0000269|PubMed:20359319, ECO:0000269|PubMed:21917775, ECO:0000269|PubMed:23364391, ECO:0000269|PubMed:23743246, ECO:0000269|PubMed:24742911}. Note=The disease is caused by variants affecting the gene represented in this entry. |
Target Relevance information above includes information from UniProt accession: P14136 |
The UniProt Consortium |
Data
Publications
Publications
pmid | title | authors | citation |
---|---|---|---|
36828035 | WWOX P47T partial loss-of-function mutation induces epilepsy, progressive neuroinflammation, and cerebellar degeneration in mice phenocopying human SCAR12. | Tabish Hussain, Kevin Sanchez, Jennifer Crayton, Dhurjhoti Saha, Collene Jeter, Yue Lu, Martin Abba, Ryan Seo, Jeffrey L Noebels, Laura Fonken, C Marcelo Aldaz | Prog Neurobiol 223:102425 |
36640336 | Neuronal and astrocytic contributions to Huntington's disease dissected with zinc finger protein transcriptional repressors. | Mohitkumar R Gangwani, Joselyn S Soto, Yasaman Jami-Alahmadi, Srushti Tiwari, Riki Kawaguchi, James A Wohlschlegel, Baljit S Khakh | Cell Rep 42:111953 |
36633130 | ASK1 inhibitor NQDI?1 decreases oxidative stress and neuroapoptosis via the ASK1/p38 and JNK signaling pathway in early brain injury after subarachnoid hemorrhage in rats. | Jiajia Duan, Wen Yuan, Juan Jiang, Jikai Wang, Xiaoxin Yan, Fei Liu, Aihua Liu | Mol Med Rep 27:N/A |
36614107 | Cerebral Folate Metabolism in Post-Mortem Alzheimer's Disease Tissues: A Small Cohort Study. | Naila Naz, Syeda F Naqvi, Nadine Hohn, Kiara Whelan, Phoebe Littler, Federico Roncaroli, Andrew C Robinson, Jaleel A Miyan | Int J Mol Sci 24:N/A |
36593462 | Intracellular deposits of amyloid-beta influence the ability of human iPSC-derived astrocytes to support neuronal function. | Evangelos Konstantinidis, Benjamin Portal, Tobias Mothes, Chiara Beretta, Maria Lindskog, Anna Erlandsson | J Neuroinflammation 20:3 |
Protocols
relevant to this product |
---|
Western blot IHC ICC |
Documents
# | SDS | Certificate | |
---|---|---|---|
Please enter your product and batch number here to retrieve product datasheet, SDS, and QC information. |